{
    "over_18_initiation_no_weightloss_agent_bmi_>27":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Documented baseline body mass index (BMI) ≥ 27 kg/m^2.",
                    "validation": "An initial BMI of less than 27 kg/m^2 is unlikely to be approved."
                },
                {
                    "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "This is not required, but including may help improve the chances of approval."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "This is not required, but including may help improve the chances of approval."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with other weightloss medications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "over_18_initiation_no_weightloss_agent_bmi_>30":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Documented baseline body mass index (BMI) ≥ 30 kg/m^2.",
                    "validation": "An initial BMI of less than 30 kg/m^2 is unlikely to be approved."
                },
                {
                    "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with other weightloss medications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "over_18_initiation_with_weightloss_agent_bmi_>30":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Documented baseline body mass index (BMI) ≥ 30 kg/m^2.",
                    "validation": "An initial BMI of less than 30 kg/m^2 is unlikely to be approved."
                },
                {
                    "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber has provided information supporting the anticipated success of repeating therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "over_18_initiation_with_weightloss_agent_bmi_>27":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Documented baseline body mass index (BMI) ≥ 27 kg/m^2.",
                    "validation": "An initial BMI of less than 27 kg/m^2 is unlikely to be approved."
                },
                {
                    "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "over_18_initiation_south_asian_no_weightloss_agent":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Documented baseline body mass index (BMI) ≥ 25 kg/m^2.",
                    "validation": "An initial BMI of less than 25 kg/m^2 is unlikely to be approved."
                },
                {
                    "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "over_18_initiation_south_asian_with_weightloss_agent":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Documented baseline body mass index (BMI) ≥ 25 kg/m^2.",
                    "validation": "An initial BMI of less than 25 kg/m^2 is unlikely to be approved."
                },
                {
                    "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "below_18_initiation_no_weightloss_agent_bmi_>85":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 85th percentile for age and gender.",
                    "validation": "Wegovy is unlikely to get approved for BMI below 85th percentile."
                },
                {
                    "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "below_18_initiation_no_weightloss_agent_bmi_>95":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 95th percentile for age and gender.",
                    "validation": "Wegovy is unlikely to get approved for BMI below 95th percentile."
                },
                {
                    "label": "Document the patient has not tried a targeted weight loss agent in the past 12 months.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "below_18_initiation_with_weightloss_agent_bmi_>85":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 85th percentile for age and gender.",
                    "validation": "Wegovy is unlikely to get approved for BMI below 85th percentile."
                },
                {
                    "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss agent.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "below_18_initiation_with_weightloss_agent_bmi_>95":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document the patient has a diagnosis of obesity, confirmed by a body mass index (BMI) ≥ 95th percentile for age and gender.",
                    "validation": "Wegovy is unlikely to get approved for BMI below 95th percentile."
                },
                {
                    "label": "Document the patient has tried a targeted weight loss agent for a previous course of therapy in the past 12 months AND the prescriber anticipates success with repeating therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient has been on a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications for a minimum of 6 months prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient did not achieve a weight loss of 1 pound or more per week while on the weight loss regimen prior to initiating therapy with Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss agent.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is newly starting therapy or has received less than 52 weeks (1 year) of therapy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is prescribed a dose escalation: Weeks 1-4: 0.25 mg, Weeks 5-8: 0.5 mg, Weeks 9-12: 1 mg, Weeks 13-16: 1.7 mg, Weeks 17-onward: 2.4 mg.",
                    "validation": "If patient does not tolerate the maintenance dose of 2.4 mg, the dose can be temporarily decreased to 1.7 mg for 4 weeks. After 4 weeks increase Wegovy to maintenance dose of 2.4 mg weekly. Discontinue Wegovy if the patient cannot tolerate 2.4 mg dose."
                }
            ]
        },
    "over_18_continuation_under_52_weeks":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document patient has recieved less than 52 weeks of therapy on the 2.4mg dose.",
                    "validation": "A dose of 1.7 mg may be prescribed for 4 weeks if the patient can not tolerate the 2.4 mg dose."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        },
    "over_18_continuation_over_52weeks":
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document patient has achieved and is maintained a reduction of BMI of at least 5% from baseline.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission.."
                }, 
                {
                    "label": "The requested dose is 1.7mg or 2.4mg.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weightloss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        },
    "below_18_continuation_over_52weeks": 
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document patient has achieved and is maintained a reduction of BMI of at least 5% from baseline.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "The requested dose is 1.7mg or 2.4mg.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document current BMI is greater than 85th percentile for age and gender.",
                    "validation": "A current BMI of less than 85th is unlikely to be approved."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weight loss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        },
    "below_18_continuation_under_52weeks": 
        {
            "header": "Verify Prescriber and Patient Documentation",
            "items": [
                {
                    "label": "Document patient has received less than 52 weeks of therapy on the 1.7 or 2.4mg dose.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document current BMI is greater than 85th percentile for age and gender.",
                    "validation": "A current BMI of less than 85th percentile is unlikely to be approved."
                },
                {
                    "label": "Document the patient will NOT be using Wegovy in combination with another GLP-1 receptor agonist agent or other weight loss medication.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document the patient is currently on and will continue a weight loss regimen of a low-calorie diet, increased physical activity, and behavioral modifications.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 or have a history of pancreatitis.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                },
                {
                    "label": "Document that the patient does NOT have a known hypersensitivity to semaglutide or any of the ingredients in Wegovy.",
                    "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
                }
            ]
        }
}
